In humans, three types of influenza virus, types A, B, and C, have been associated with epidemics of respiratory disease. Type A and B influenza viruses can cause a wide spectrum of illness, including lower respiratory tract disease, pneumonia, and even, in the case of type A influenza virus, encephalopathy and encephalitis. On the other hand, infections with type C influenza virus are limited to the upper respiratory tract (20) . In the past, all three types of influenza virus were considered to be members of the genus Orthomyxovirus (27) , but more recently, type C influenza virus has been placed in a separate genus (21) .
The influenza viruses are divided into types on the basis of antigenic differences on the nucleoprotein and matrix proteins. Type A influenza viruses are further subtyped on the basis of antigenic differences on the external glycoproteins, the hemagglutinin (HA) and the neuraminidase (NA) proteins. Currently, there are 14 distinct HA subtypes and 9 NA subtypes, although historically, human type A influenza virus subtypes have been limited to H1, H2, and H3 and, in the past 90 years, to N1 and N2. The amount of amino acid similarity among subtypes of HA ranges from 25 to 80% (1) , and among NA subtypes the amount of similarity ranges from 42 to 57% (8) 
There is a further level of variation, termed antigenic drift, that is observed on the HA and NA proteins of isolates of viruses within subtypes and that results from the accumulation of single amino acid changes at antigenic sites defined with monoclonal antibodies. The HA and NA proteins of type B influenza viruses also undergo antigenic drift, but sequence changes do not accumulate to result in definable subtypes, as is the case for type A influenza viruses (17) .
Confirmation of diagnoses of infection with type A or B influenza virus is not routinely carried out, but it may be required when amantadine prophylaxis of susceptible contacts of type A influenza virus infection is considered. A quick method for direct typing is desirable since type B influenza virus is not susceptible to inhibition by amantadine. As well, rapid subtyping of current strains of influenza virus has epidemiological value.
The usual method for subtyping influenza viruses involves expansion of virus in tissue culture or embryonated hens' eggs prior to typing and subtyping by hemagglutination inhibition, enzyme-linked immunosorbent assay (ELISA), or immunofluorescence. More currently, several modified ELISAs with increased sensitivities have been described (3, 5, 10, 14, 26) . Another approach to the rapid detection and identification of influenza viruses is the use of PCR for the detection and amplification of viral nucleic acids. The use of PCR for the detection of pathogens has been explored in many viral systems, including hepatitis B virus (15) and papillomavirus (25) and RNA viruses such as human immunodeficiency virus (9), arenaviruses (16, 18) , rotaviruses (12, 13) , flaviviruses (11) , and alphaviruses (24) . Oligonucleotide primers and assays have been designed for differentiating the three types of influenza virus (6, 7) as well as for subtyping type A influenza virus HAs (29, 30) and NAs (30) . Other workers have designed oligonucleotide primers for the detection of all type A influenza viruses (4, 22) or single subtypes of type A influenza virus (2) .
We designed several sets of primer pairs that can be used together in reverse transcription-PCR (RT-PCR) to detect and distinguish type B influenza virus and type A influenza virus subtypes H1 and H3. Used in conjunction with our primers for N1 and N2, our method allows for the rapid and complete identification of suspected influenza isolates.
MATERIALS AND METHODS
Cells and virus stocks. Strains of type A and B influenza virus were from Laboratory Centre for Disease Control (Ottawa, Ontario, Canada) stocks that had been propagated in embryonated hens' eggs. The viruses used were A/Singapore/1/57 (H2N2), A/Hong Kong/1/68 (H3N2), A/Shanghai/11/87(H3N2), A/Puerto Rico/8/34 (H1N1), A/Taiwan/1/86(H1N1), B/Panama/45/90, and B/Singapore/222/79. Stocks for specificity and sensitivity assays were grown in MDCK cells in minimal essential medium (MEM) supplemented with 5% newborn calf serum-1% L-glutamine-penicillin-streptomycin (100 U of penicillin G per ml and 100 g of streptomycin sulfate per ml)-1 g of trypsin per ml. Virus stocks were titrated on MDCK monolayers in six-well plates (Costar, Cambridge, Mass.). Monolayers were washed with phosphate-buffered saline (PBS) and were then plated with 10-fold dilutions of virus in PBS plus 0.2% bovine serum albumin (BSA; Sigma, St. Louis, Mo.). After adsorption for 1 h at 33ЊC, the inoculum was removed and the cells were overlaid with MEM supplemented with 0.2% BSA-100 g of DEAE dextran (Sigma) per ml-0.5% agar (Oxoid, Basingstoke, England)-1 g of trypsin per ml-2.2 mg of NaHCO 3 per ml. After 2 days at 33ЊC, the plates were fixed with 10% formalin in PBS and were stained with crystal violet.
Clinical specimens. Clinical samples from patients with respiratory disease were obtained from the Laboratory Centre for Disease Control and from the Children's Hospital of Eastern Ontario. Samples from the Laboratory Centre for Disease Control were known to be positive for influenza virus, but RT-PCR was carried out without previous knowledge of the type or subtype of the virus. Samples from the Children's Hospital of Eastern Ontario were either throat washes or nasopharyngeal suctions. The latter samples were treated at the hospital with acetylcysteine to solubilize the mucus prior to processing (19) . The samples were then split into two aliquots; one aliquot was used for serological typing in the hospital laboratories (28) , the other aliquot was sent for analysis by RT-PCR. The clinical specimens required no special medium, but were kept frozen until extraction of RNA.
Oligonucleotide primers and sequencing. All primer pairs were synthesized on an Applied Biosystem model 3808 DNA synthesizer at the Biotech Research Institute, University of Ottawa. Sequencing of amplified products was performed on an Applied Biosystems 373A DNA sequencer in the DNA Core Facility, Laboratory Centre for Disease Control.
cDNA reaction. Viral RNA was extracted and precipitated from the samples as follows. The samples were mixed with an equal volume of TE buffer (10 mM Tris, 1 mM EDTA [pH 8.0]) with 1% sodium dodecyl sulfate-200 g of proteinase K (Boehringer-Mannheim, Laval, Quebec, Canada) per ml, and the mixture was incubated for 30 min at 56ЊC. The digested material was extracted once with phenol-chloroform (phenol-chloroform-isoamyl alcohol [25:25:1] ) and once with chloroform before precipitation with 3 volumes of sodium acetate-ethanol (23) . The RNA was then pelleted, dried under vacuum, and resuspended in the reaction mixture for RT.
cDNA complementary for viral RNA was synthesized by using murine leukemia virus reverse transcriptase or murine leukemia virus superscript reverse transcriptase (both from Bethesda Research Laboratories, Burlington, Ontario, Canada). Each reaction was carried out in 20 l of RT buffer (Bethesda Research Laboratories)-1.25 mM deoxynucleoside triphosphates (dNTPs; Pharmacia, Quebec, Quebec, Canada)-10 mM dithiothreitol-100 ng each of the appropriate primers-100 U of reverse transcriptase. After incubation for 1 h at 37ЊC, the cDNA was used immediately for PCR or was stored at Ϫ20ЊC. PCR. PCR mixtures (100 l per reaction) contained 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2 mM MgCl 2 , 0.25 mM (each) dNTP (Pharmacia), 100 ng of each primer, and 2 U of Taq polymerase (Bethesda Research Laboratories). Half of the cDNA reaction mixture, or 10 l, was used in each PCR. Amplification was carried out for 40 cycles, as follows: denaturation for 1 min at 94ЊC, hybridization at 55ЊC for 2 min, and elongation at 72ЊC for 3 min. A final cycle with an elongation step of 7 min was included at the end. One-fifth of the amplified product was electrophoresed on 1.2% agarose (BDH, Toronto, Ontario, Canada) in Tris-borate buffer. Gels were stained after electrophoresis in 2 g of ethidium bromide per ml and were photographed.
Restriction digestion of type-specific products was carried out with ApaLI (New England Biolabs, Mississauga, Ontario, Canada) and EcoRI (Pharmacia) according to the manufacturers' directions.
RESULTS

Design of primers.
Three sets of oligonucleotide primers were designed; the first set differentiates type A and B influenza viruses, the second set differentiates the H1 and H3 subtypes of type A influenza virus HA, and the third set differentiates the N1 and N2 subtypes of NA. The gene for the nucleoprotein was chosen as the target for type A influenza virus-specific primers, because this gene is highly conserved among the subtypes of type A influenza viruses, but is significantly distinct from the nucleoprotein of type B influenza viruses (20) . These primers were designed after sequence comparison of five strains of type A influenza virus representing the three subtypes of type A influenza virus known to infect humans. The primers amplify a conserved fragment of 306 bp ( Table 1 ). The type B influenza virus-specific primer pair amplifies 226-bp fragments from the gene of the first nonstructural protein (NS1) by using segments of the gene that show no homology with type A influenza virus strains.
Design of the subtype-specific primers was done by multiple sequence alignment facilitated by the PILEUP program from the Sequence Analysis Software Package by Genetics Computer Group Inc., Madison, Wis. A comparison was made of the HA genes of 12 strains of type A influenza virus subtype H1, 9 strains of type A influenza virus subtype H3, and a single H2 isolate. Primers were designed to amplify a fragment of 611 bp from H1 and a fragment of 976 bp from H3. There was one ambiguity in the region chosen for the second primer of H1; 11 sequences had an adenine at the second base from the 5Ј end; the 12th sequence had a guanine. We chose to substitute an inosine at this position (Table 1) . Because the single available sequence of H2 shows considerable homology to both H1 and H3, we were unable to arrive at a set of primers that would amplify a fragment of the H2 gene distinguishable from the amplicons of H1 and H3 on electrophoresis.
The NA-specific primers were chosen after comparison of 7 N1 and 12 N2 sequences, and use of these primers allows determination of NA without running nested PCR as reported by others (30) . The amplified products for N1 and N2 are 615 and 434 bp, respectively ( Table 1) .
Specificities of primer pairs. Initially, the specificities of the primer pairs were tested with purified RNAs from four viruses, A/Puerto Rico/8/34 (H1N1), A/Singapore/1/57 (H2N2), A/Hong Kong/1/68 (H3N2), and B/Singapore/222/79 (B). The type A influenza virus-specific primers amplified a fragment of the appropriate size from all three subtypes of type A influenza virus, but did not amplify the fragment when the subtypes were assayed with type B influenza virus. Similarly, the type B influenza virus-specific primers amplified a product only from type B influenza virus (Fig. 1) . The primers specific for subtypes of HA and NA also amplified products only from the relevant influenza strains ( Fig. 2A and B) . We determined all amplicons to be influenza type and subtype specific by sequence analysis of amplicons.
Conditions for RT-PCR. Having established that the primers were specific for the desired genes of influenza virus, we determined the best conditions for running the reactions. For synthesis of cDNA, we tried random primers, as described by Zhang and Evans (30) , as well as a mixture of influenza virusspecific primers. For the latter, we mixed the first primer of each pair specific for H1, H3, and B plus primers specific for the two NA subtype genes (N1, N2). For the amplification step, half of the cDNA was added to a reaction mixture that included the primers for influenza virus types B, A/H1, and A/H3, and 40 cycles of amplification were carried out. The second aliquot of cDNA was amplified with a mixture of N1 and N2 primers under the same conditions. Such a protocol allows identification of currently circulating type B, H1N1, or H3N2 strains with a single RT reaction and two amplification reactions. We found little difference in our results when using random primers rather than specific primers for the RT step. Subsequently, we used random primers for all RT reactions. Having established the conditions for RT-PCR, we confirmed the specificities and broad applicabilities of the primers by carrying out the reactions (B/HA and NA) on several more strains of influenza virus than we initially used, including the Sensitivities of primer pairs. We tested sensitivity using the same virus stocks used in the experiments described above. Virus was serially diluted to give a specified number of PFU per sample, and then the RNA was extracted and the cDNA was synthesized with random primers. The cDNA was then divided into two aliquots, one for B/HA-specific PCR and the other for NA-specific PCR. All of the primer pairs except those specific for H3 consistently detected between 25 and 50 PFU, although occasionally as few as 3 PFU could be detected. The H3-specific primers appeared to be less sensitive, detecting 50 to 100 PFU.
Assay of clinical specimens. Clinical specimens collected at the Children's Hospital of Eastern Ontario during the months of December 1992 and January and February of 1993 were analyzed for influenza virus by RT-PCR. The samples were tested without knowledge of the diagnosis carried out in the hospital laboratory. RNA was extracted from 150 to 200 l of sample (or whatever volume was present if it was less than this), and RT-PCR was carried out as outlined above. Usually, one-half of the cDNA was used for B/HA-specific PCR amplification and the other half was used for NA-specific PCR amplification. However, when the volume of clinical material was small, all of the cDNA was used for B/HA differentiation, and typing of the NA was not carried out. Ninety-eight samples were analyzed, and the results are presented in Table 2 .
Eleven samples identified as type B influenza virus by culture were detected by RT-PCR. One specimen positive for type B influenza virus by culture was negative by RT-PCR, and one specimen negative by culture was positive by RT-PCR. Of the eight samples identified as type A influenza virus by culture, seven were detected by RT-PCR and two culture-negative samples were positive for type A influenza virus by RT-PCR. One of these two samples was culture positive for respiratory syncytial virus. However, of the remaining specimens, 30 were culture positive for respiratory syncytial virus, 4 were culture positive for human parainfluenza virus type 3, 1 was culture positive for adenovirus, 2 were culture positive for enterovirus, and none of these was positive for influenza virus by either culture or RT-PCR.
When the results are analyzed for efficiency in typing or subtyping, it is clear that the B/HA mixture was able to correctly type the specimens positive for type B influenza virus. Of the seven specimens in which type A influenza virus was detected, two were negative by the first RT-PCR but were positive when the remaining cDNA was amplified with the type A influenza virus-specific primers. The other five samples were subtyped for HA, but for only one was cDNA available for NA subtyping by PCR. Because we tested the N1 and N2 primers 
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DISCUSSION
Several strategies for the rapid detection of influenza viruses, including immunofluorescence, enzyme immunoassays, and RT-PCR, have been presented in the past few years. Rapid immunoassays tend to be type specific and limited to type A isolates (3, 5, 10, 14, 26) . PCR methods have been designed to be type specific, detecting type A viruses only (4, 22) , or to distinguish between type A, B, or C virus (6, 7). Subtypespecific primers have been designed to detect single subtypes of type A influenza virus (2) or to differentiate between subtypes of HAs (29, 30) and NAs (30) . However, we are the first to design several sets of primers that can be used together to detect both type A and type B influenza viruses and, at the same time, subtype type A isolates as either H1 or H3. As well, we have designed unique primers for subtyping the NA in a parallel reaction without the need to do a second, nested amplification as described by others (30) . Another advantage of our system is that all of our primers were designed to anneal at 55ЊC, so all reactions can be run under identical conditions regardless of the virus template.
We tested the specificities of our primers and the conditions for the assay on a series of known samples prior to evaluation of clinical specimens. We were able to amplify the desired products from these samples using the same conditions for RT-PCR regardless of which primer pairs were used. Under these conditions the assay could detect between 6 and 50 PFU of virus, which translates to 6 ϫ 10 2 to 5 ϫ 10 3 particles, if one assumes a particle/PFU ratio of 100:1. Using protocols similar to ours and detecting products by agarose gel electrophoresis, some investigators report sensitivities of 1 to 2 PFU for typespecific primers (6), whereas others observed this level of sensitivity only after a second cycle PCR (29) or after Southern blotting (22) . Other investigators have increased the sensitivity of RT-PCR by doing nested PCR (30) or by detecting the amplified DNA by enzyme-linked detection of the amplicon hybridized to an RNA probe (4), but in the latter instance, culturable samples with 10 0.8 50% tissue culture infective doses or less were still negative. Unlike others (7), we were never able to consistently amplify products from virus samples that had not been digested with proteinase K in the presence of sodium dodecyl sulfate, and this then necessitated extraction and precipitation of RNA prior to cDNA synthesis, a procedure which is likely to reduce sensitivity. The increased sensitivity reported by others might also be accounted for by the use of guanidine thiocyanate in extractions of RNA, because this procedure is reported to be more efficient in inhibiting RNase activity (23) .
When we assessed our protocol on clinical specimens, we confirmed the specificities of our primers, because only 1 of 37 samples positive by culture for other respiratory viruses yielded a positive result for influenza virus after RT-PCR, and this is likely to be a true-positive result rather than mispriming of an irrelevant virus. We also found two other culture-negative samples positive by our assay, which may again be true detection of virus that was not culturable. Others have reported virus detection by RT-PCR in samples negative by culture, particularly in samples that were collected more than 4 days after infection (4) .
Four samples yielded negative results by B/HA RT-PCR that were positive by culture, but two of these samples were typeable when type A-specific primers were used. Hence, our assay detected 18 of 20 or 90% of samples positive by culture. After a single PCR with primers specific for H1 and H3 and detection by ethidium bromide staining of products after agarose gel electrophoresis, Yamada et al. (29) were able to detect virus in only 3 of 17 clinical specimens. Claas et al. (7) had more success and detected 92% of samples also positive for influenza virus by culture. If all samples positive by RT-PCR are included as true positives, then our assay detected 21 of 23 (91%) influenza virus-positive specimens, whereas culture methods were only 87% successful in detecting the presence of the virus.
Direct immunofluorescent and rapid commercial enzyme immunoassay methods of influenza virus antigen detection may have shorter times to a positive result than RT-PCR, but they may have decreased sensitivities and low negative predictive values. This may then necessitate lengthy follow-up of a negative test result for 1 to 2 weeks in culture. We did not compare RT-PCR with these methods, but Claas et al. (7) showed that their influenza virus RT-PCR carried out on clinical specimens had a sensitivity and specificity superior to those of direct immunofluorescence but comparable to those of cell culture combined with immunofluorescence. Nevertheless, until sensitive and specific RT-PCR methods are developed for all of the major respiratory viruses, laboratories may be reluctant to adopt this method for influenza viruses while continuing to rely on culture and immunofluorescence for the detection of other respiratory viruses. Subtyping of HA and NA are largely the concerns of public health surveillance. Therefore, currently, the RT-PCR method of subtyping may have its greatest usefulness in reference, epidemiological applications rather than in clinical situations. However, when distinction between type A and type B influenza viruses is necessary for patient management decisions, type-specific RT-PCR offers a higher degree of confidence in excluding type A influenza virus infection when type B influenza virus is detected.
In summary, the RT-PCR protocol presented in this report is equally but not more efficient than standard culture methods in detecting influenza virus in clinical specimens, although it has the theoretical advantage of being able to detect viral RNA below cultivable levels of viruses (4) and in specimens in which   FIG. 3 . RT-PCR of clinical specimens. RNAs from clinical specimens representing three influenza viruses, types A/H1N1, A/H3N2, and B, were used as templates for RT with random primers, and then cDNA was amplified with a mixture of B-H1-H3 primers (lanes 1, 3, and 5) or N1-N2 primers (lanes 2, 4, and 6). Control reactions were carried out on purified RNA from A/Shanghai/11/87 (H3N2), A/Taiwan/1/86 (H1N1), and B/Panama/45/90 (lanes 8, 10, and 12, respectively), and N1-N2 reactions were carried out on the same cDNAs (lanes 9, 11, and 13, respectively). Lanes marked M contain molecular mass markers, and negative controls with water as template are in lanes 7 and 14.
virus may not be viable. Under ideal circumstances, virus culture, serological characterization of HA, and biochemical characterization of NA might be accomplished in 1 week with considerable technical time input. Another major advantage of RT-PCR over culture is the rapidity (48 h) with which diagnosis and characterization can be completed; in the same process it allows typing and subtyping of HA in a single RT-PCR step and, if desired, simultaneous subtyping of NA in the same cDNA template.
